



GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

29th October 2024

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sirs,

Subject: Media release: Q2 of 2024-25

Please find enclosed a press release issued by the Company in respect of financial results for the quarter ended 30th September 2024.

This is for your information and record.

Yours faithfully
For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

CIN: L24239MH1924PLC001151



**GlaxoSmithKline Pharmaceuticals Limited crosses Rs.1000 crore in Revenue from Operations
Declares Special Interim Dividend of Rs. 12 per share to commemorate 100 years in India**

Mumbai, India: GlaxoSmithKline Pharmaceuticals Limited (GSK) today announced its financial results for the quarter ended September 30, 2024. Revenue from operations for the quarter grew by 5% to cross INR 1000 crores. Profit After Tax (PAT) for the quarter INR 249 crores grew by 15%.

For the half year ended 30th September 2024, the company delivered Rs 1811 crores Revenue from Operations recording a growth of 7%. Profit before exceptional items and tax for the half year at Rs 583 crores improved by 27% with EBITDA margins at 30%.

The Board of Directors at its meeting held on 29th October 2024 declared a special interim dividend of Rs. 12 per equity share of face value of Rs. 10 each.

While key brands held their market share and continued to stay in line with the respective category performance, the represented market experienced sluggish growth in General Medicines. Augmentin continues to be the No.1 brand in the overall Indian pharma market and respiratory portfolio led by Nucala and Trelegy continued to gain market share.

The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market. In the Adult vaccines segment, GSK continues to build on the momentum of its Shingrix Herpes Zoster Vaccine (recombinant, adjuvanted), advancing the Adult Immunisation category in India through innovative go-to-market (GTM) strategies.

Commenting on the results, Mr. Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, "As we mark our centenary year in India, we are happy to announce a special interim dividend to our shareholders.

Our performance reflects our commitment to sustainable growth and innovation. Furthermore, our shingles diseases awareness campaign featuring Mr. Amitabh Bachchan has significantly elevated the discussion around Shingles prevention, reinforcing our focus in preventive healthcare in India."

About GlaxoSmithKline Pharmaceuticals Limited (GSK)



GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GSK plc, a science-led global healthcare company with a purpose to unite science, technology, and talent to get ahead of disease together. For more information, visit GSK-India.com.

Media Contact

Ransom D' Souza - ransom.a.dsouza@gsk.com

Communications & Government Affairs